Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Link
https://link.springer.com/content/pdf/10.1007/s11886-022-01775-5.pdf
Reference75 articles.
1. • Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol. 2016;67:353–61. The IMPROVE-IT trial included 18,144 patients who were randomized to receive intensive lipid-lowering therapy (ezetimibe/statin) or placebo/statin. The intensive treatment group had fewer MIs and strokes which led to significant reduction in events following acute coronary syndrome. Overall, this suggests improved clinical outcomes with aggressive lipid-lowering therapies.
2. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.
3. • Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207. This clinical trial demonstrates the utility of CRP as an atherogenic biomarker. In healthy patients who had LDL-C < 130 but CRP > 2, treatment with rosuvastatin was associated with lower incidence of major cardiovascular events over median follow up of 1.9 years.
4. • Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–71. This randomized, double-blind trial tested the effect of an immune-modulating antibody, canakinumab, on reduction in cardiovascular events. This was a positive trial and as such demonstrated that cardiovascular risk is related to inflammation which may suggest markers of inflammation like CRP, if elevated, may be heralds of future ASCVD.
5. Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park J-G, Murphy SA, White JA, Tershakovec AM, Cannon CP, Braunwald E. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol : a prespecified analysis of the IMPROVE-IT Trial. JAMA Cardiol. 2017;2:547–55.
Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Therapies in Disorders of Lipid Metabolism and Obesity;Endocrinology;2023-12-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3